GILEAD SCIENCES, INC. (GILD)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. It focuses on unmet medical needs in virology, oncology and inflammation, and says it has pursued medical breakthroughs for more than three decades. The company also earns royalty, contract and other revenues from outbound licenses of its intellectual property, sales of certain intellectual property and payments from collaboration partners.

In 2025 the commercial portfolio included more than 25 therapies. In HIV, these include Biktarvy, Descovy (also approved for PrEP), Genvoya, Odefsey, Sunlenca, Symtuza (commercialized by Janssen, with Gilead receiving a revenue share) and the newly approved twice-yearly PrEP product Yeztugo (Yeytuo in the EU). In liver disease, products include Epclusa and Vemlidy for hepatitis C and B, and Livdelzi for primary biliary cholangitis. In oncology, they include the CAR T-cell therapies Yescarta and Tecartus and the antibody-drug conjugate Trodelvy. AmBisome treats serious invasive fungal infections, and Veklury treats COVID-19. Late-stage candidates include bulevirtide for hepatitis delta, once-yearly lenacapavir for PrEP, lenacapavir combinations for HIV treatment, and anitocabtagene autoleucel for multiple myeloma with Arcellx. Others are sacituzumab govitecan in additional breast, lung and endometrial cancer settings, and domvanalimab with zimberelimab with Arcus. Merck is a collaborator on several programs.

Gilead's customers are physicians, hospitals, clinics and other healthcare providers, reached through wholesalers, distributors and corporate partners. It operates in more than 35 countries with marketing subsidiaries there. Historically about 90% of gross U.S. product sales have gone to three wholesalers, Cardinal Health, Cencora and McKesson, and their specialty distributor affiliates. In Europe and other markets, it sells through its own commercial teams, third-party distributors or corporate partners.

The company is headquartered in Foster City, California. It uses third-party contract manufacturers for some products and relies heavily on contract research organizations for most clinical studies. It competes with large pharmaceutical and biotechnology companies, specialized pharmaceutical firms, academic and research institutions, and new branded or generic products. Competition is based on efficacy, safety, tolerability, ease of use, price and reimbursement coverage, and payers exert pricing pressure as products mature. Patents, supplementary protection certificates, regulatory exclusivities and trade secrets protect its products, and it adds to its portfolio through collaborations, in-licensing and acquisitions.